2010 Fiscal Year Final Research Report
Basic study for development of a novel therapeutic strategy, targeting the extracellular ATP hydrolyzing enzyme, CD39 to protect from vascular endothelial disorder.
| Project/Area Number |
20590088
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Takasaki University of Health and Welfare |
|---|
Principal Investigator |
MATSUOKA Isao Takasaki University of Health and Welfare, 薬学部, 教授 (10145633)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOMOGIDA Sinnichi 高崎健康福祉大学, 薬学部, 准教授 (90250802)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 心血管 / 炎症 / 病態生理 / 細胞内情報伝達 |
|---|
| Research Abstract |
Vascular endothelial cells express highly active ecto-nucleoside diphosphohydrolase 1 (CD39) that hydrolyzes extracellular ATP and ADP into AMP. CD39 plays a critical role in the regulation of vascular homeostasis. In this study, we found that various inflammatory cytokines including IL-1β, TNF-α and IFN-γ, impaired the ATP hydrolysis and CD39 mRNA expression, whereas HMG-CoA reductase inhibitor (statin) caused time- and concentration-dependent increase in ATP and ADP hydrolysis accompanied by an up-regulation of CD39 mRNA expression. Statin-induced up-regulation of CD39 mRNA expression was involved in an inhibition of small G protein Rho function. These results suggest that the inhibition of Rho-dependent signaling is a promising strategy to increases vascular CD39 expression.
|
Research Products
(17 results)
